Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Enzalutamide, compared with bicalutamide, is effective in improving clinical outcomes regardless of age in chemotherapy-naïve men with metastatic castration-resistant prostate cancer, reports a recent study.
In Asian patients with localized prostate cancer, high dose rate (HDR) brachytherapy following an external beam radiotherapy (EBRT) achieves effective disease control while minimizing toxicity, a recent Singapore study has shown.
Preoperative biopsy Gleason grade (4 + 4 vs any Gleason pattern 5) subclassification of high-risk prostate cancer identifies men at highest risk for progression, according to a study. Furthermore, any Gleason 5 on biopsy correlates with a higher risk of metastasis, as well as prostate cancer-specific and overall mortality.
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Enzalutamide demonstrates antitumour activity for up to 3 years in patients with hormone-naïve prostate cancer, according to a follow-up analysis of a phase II trial. Specifically, results for bone mineral density, global health status and safety at year 3 are similar to those at year 2.
Pomegranate juice and extract are safe but do not favourably influence outcomes in prostate cancer patients with biochemical recurrence, a study has shown. However, a subset of BCR patients with the manganese superoxide dismutase AA genotype appear to respond positively to the antioxidant effects of pomegranate.
Active surveillance on patients with localized prostate cancer results in a decreased rate of active surveillance failure, prostate cancer specific mortality and metastases regardless of baseline risk, according to a recent study.
Both denosumab and bisphosphonates enhance bone mineral density (BMD) in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy (ADT), according to a systematic review and meta-analysis. In addition, denosumab lowers the risk for radiographic vertebral fractures.